Abstract:Background: Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments for HD are yet to be developed.Methodology/Principal Findings: Here, we report a novel dual-function compound, N-6-(4-hydroxybenzyl) adenine riboside (designated T1-11) which activates the A(2A)R and a major adenosine transporter (ENT1). T1-11 was originally isolated from a Chinese medicinal herb. Molecular modeling analyses showed that T1-11 binds to the adenosine pockets of the A(2A)R and ENT1. Introduction of T1-11 into the striatum significantly enhanced the level of striatal adenosine as determined by a microdialysis technique, demonstrating that T1-11 inhibited adenosine uptake in vivo. A single intraperitoneal injection of T1-11 in wildtype mice, but not in A(2A)R knockout mice, increased cAMP level in the brain. Thus, T1-11 enters the brain and elevates cAMP via activation of the A(2A)R in vivo. Most importantly, addition of T1-11 (0.05 mg/ml) to the drinking water of a transgenic mouse model of HD (R6/2) ameliorated the progressive deterioration in motor coordination, reduced the formation of striatal Htt aggregates, elevated proteasome activity, and increased the level of an important neurotrophic factor (brain derived neurotrophic factor) in the brain. These results demonstrate the therapeutic potential of T1-11 for treating HD.Conclusions/Significance: The dual functions of T1-11 enable T1-11 to effectively activate the adenosinergic system and subsequently delay the progression of HD. This is a novel therapeutic strategy for HD. Similar dual-function drugs aimed at a particular neurotransmitter system as proposed herein may be applicable to other neurotransmitter systems (e. g., the dopamine receptor/dopamine transporter and the serotonin receptor/serotonin transporter) and may facilitate the development of new drugs for other neurodegenerative diseases.

Drugging unconventional targets: insights from Huntington's disease.

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov

Huntington's Disease: Molecular Basis of Pathology and Status of Current Therapeutic Approaches.

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

A New Drug Design Targeting The Adenosinergic System For Huntington'S Disease

Therapy development in Huntington disease: From current strategies to emerging opportunities

Molecular Strategies to Target Protein Aggregation in Huntington's Disease

Gene Targeting Techniques for Huntington’s Disease

Complex Pathogenesis and Therapeutic Strategies

Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide

ATTEC: a Potential New Approach to Target Proteinopathies

The Huntington's disease drug pipeline: a review of small molecules and their therapeutic targets

Progress in studies of gene therapy for Huntington's disease

Emerging pharmacological approaches for Huntington's disease

Neuronal Store-Operated Calcium Entry Pathway as a Novel Therapeutic Target for Huntington's Disease Treatment

Drugging “undruggable” Neurodegenerative Disease Targets with Small Molecules

Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis

Huntington's Disease: Latest Frontiers in Therapeutics